Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
ADC ID |
DRG0DOYAV
|
|||||
---|---|---|---|---|---|---|
ADC Name |
MUC16 PNU ADC2-4
|
|||||
Synonyms |
MUC16-PNU-ADC2-4
Click to Show/Hide
|
|||||
Organization |
Genentech, Inc.
|
|||||
Drug Status |
Investigative
|
|||||
Indication |
In total 2 Indication(s)
Fallopian tube cancer [ICD11:2C74]
Investigative
Pancreatic cancer [ICD11:2C10]
Investigative
|
|||||
Drug-to-Antibody Ratio |
3-4
|
|||||
Structure | ||||||
Antibody Name |
Anti-MUC16 Anti-ody 3A5
|
Antibody Info | ||||
Antigen Name |
Mucin-16 (MUC16)
|
Antigen Info | ||||
Payload Name |
Undisclosed
|
|||||
Linker Name |
MUC16 PNU ADC2-4 linker
|
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Revealed Based on the Cell Line Data
Standard Type | Value | Units | Cell Line | Disease Model |
---|---|---|---|---|
Half Maximal Inhibitory Concentration (IC50) |
337
|
ng/mL
|
EoL-1 cells
|
Chronic eosinophilic leukemia
|
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 64.52% (Day 14) | Positive CD33 expression (CD33+++/++) | ||
Method Description |
Single intravenous (IV) administration of ADCs to mice bearing HL-60 AML xenografts, each conjugate (in 0.4 mg/kg) that were administered once IV at the day 0 time point.
|
||||
In Vivo Model | HL-60 CDX model | ||||
In Vitro Model | Adult acute myeloid leukemia | HL-60 cells | CVCL_0002 | ||
Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 98.28% (Day 14) | Positive CD33 expression (CD33+++/++) | ||
Method Description |
Single intravenous (IV) administration of ADCs to mice bearing HL-60 AML xenografts, each conjugate (in 0.9 mg/kg) that were administered once IV at the day 0 time point.
|
||||
In Vivo Model | HL-60 CDX model | ||||
In Vitro Model | Adult acute myeloid leukemia | HL-60 cells | CVCL_0002 |
Revealed Based on the Cell Line Data
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 337 ng/mL | Positive CD33 expression (CD33+++/++) | ||
Method Description |
The cells, at a predeterminedconcentration, were plated into 96 well plates, and, after overnight incubation at 37°C/5CO2, serialdilutions of each test article (TA) were added to the cells. Cells were incubated with test articlesfor 72 hours, and viability was detected with CellTiter-Glo reagent.
|
||||
In Vitro Model | Chronic eosinophilic leukemia | EoL-1 cells | CVCL_0258 |
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.